Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass

Cell Reports

Volumn 12, Issue 3, 2015, Pages 495-510

  Solloway, Mark J ^a,d   Madjidi, Azadeh ^a   Gu, Chunyan ^a   Eastham Anderson, Jeff ^a   Clarke, Holly J ^a   Kljavin, Noelyn ^a   Zavala Solorio, Jose ^a   Kates, Lance ^a   Friedman, Brad ^a   Brauer, Matt ^a   Wang, Jianyong ^a   Fiehn, Oliver ^b   Kolumam, Ganesh ^a   Stern, Howard ^a,c   Lowe, John B ^a   Peterson, Andrew S ^a   Allan, Bernard B ^a,d  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Infinity Pharmaceuticals Inc   (United States)

^d NGM Biopharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CASPASE 3; GLUCAGON; MAMMALIAN TARGET OF RAPAMYCIN; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME LOCALIZATION; GLUCOSE HOMEOSTASIS; LIVER METABOLISM; METABOLIC REGULATION; MOUSE; NEWBORN; NONHUMAN; PANCREAS ISLET ALPHA CELL; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CYTOLOGY; LIVER; METABOLISM;

MUS;

AMINO ACIDS; ANIMALS; CELL PROLIFERATION; GLUCAGON; LIVER; METABOLISM; MICE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84937514372     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.06.034     Document Type: Article

References (37)

1. Al-Hasani K., Pfeifer A., Courtney M., Ben-Othman N., Gjernes E., Vieira A., Druelle N., Avolio F., Ravassard P., Leuckx G., et al. Adult duct-lining cells can reprogram into β-like cells able to counter repeated cycles of toxin-induced diabetes. Dev. Cell 2013, 26:86-100.
2. Amelio I., Cutruzzolá F., Antonov A., Agostini M., Melino G. Serine and glycine metabolism in cancer. Trends Biochem. Sci. 2014, 39:191-198.
3. Bagger J.I., Knop F.K., Holst J.J., Vilsbøll T. Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes. Metab. 2011, 13:965-971.
4. Boj S.F., van Es J.H., Huch M., Li V.S.W., José A., Hatzis P., Mokry M., Haegebarth A., van den Born M., Chambon P., et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012, 151:1595-1607.
5. Bonner-Weir S. Perspective: postnatal pancreatic β cell growth. Endocrinology 2000, 141:1926-1929.
6. Chen M., Gavrilova O., Zhao W.Q., Nguyen A., Lorenzo J., Shen L., Nackers L., Pack S., Jou W., Weinstein L.S. Increased glucose tolerance and reduced adiposity in the absence of fasting hypoglycemia in mice with liver-specific Gs alpha deficiency. J.Clin. Invest. 2005, 115:3217-3227.
7. Chung C.H., Hao E., Piran R., Keinan E., Levine F. Pancreatic β-cell neogenesis by direct conversion from mature α-cells. Stem Cells 2010, 28:1630-1638.
8. Collombat P., Hecksher-Sørensen J., Krull J., Berger J., Riedel D., Herrera P.L., Serup P., Mansouri A. Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell phenotypes upon Arx misexpression. J.Clin. Invest. 2007, 117:961-970.
9. Collombat P., Xu X., Ravassard P., Sosa-Pineda B., Dussaud S., Billestrup N., Madsen O.D., Serup P., Heimberg H., Mansouri A. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 2009, 138:449-462.
10. Csibi A., Fendt S.M., Li C., Poulogiannis G., Choo A.Y., Chapski D.J., Jeong S.M., Dempsey J.M., Parkhitko A., Morrison T., et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 2013, 153:840-854.
11. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes. Metab. 2011, 13(Suppl 1):126-132.
12. Efeyan A., Zoncu R., Chang S., Gumper I., Snitkin H., Wolfson R.L., Kirak O., Sabatini D.D., Sabatini D.M. Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival. Nature 2013, 493:679-683.
13. Eisenstein A.B., Strack I. Amino acid stimulation of glucagon secretion by perifused islets of high-protein-fed rats. Diabetes 1978, 27:370-376.
14. Fiehn O., Kind T. Metabolite profiling in blood plasma. Methods Mol. Biol. 2007, 358:3-17.
15. Gelling R.W., Du X.Q., Dichmann D.S., Rømer J., Huang H., Cui L., Obici S., Tang B., Holst J.J., Fledelius C., et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA 2003, 100:1438-1443.
16. Gu G., Dubauskaite J., Melton D.A. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 2002, 129:2447-2457.
17. Gu W., Yan H., Winters K.A., Komorowski R., Vonderfecht S., Atangan L., Sivits G., Hill D., Yang J., Bi V., et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible α-cell hyperplasia and hyperglucagonemia. J.Pharmacol. Exp. Ther. 2009, 331:871-881.
18. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
19. Hayashi Y., Yamamoto M., Mizoguchi H., Watanabe C., Ito R., Yamamoto S., Sun X.Y., Murata Y. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of isletalpha-cells but not of intestinal L-cells. Mol. Endocrinol. 2009, 23:1990-1999.
20. Jiao Y., Shi C., Edil B.H., de Wilde R.F., Klimstra D.S., Maitra A., Schulick R.D., Tang L.H., Wolfgang C.L., Choti M.A., et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011, 331:1199-1203.
21. Koth C.M., Murray J.M., Mukund S., Madjidi A., Minn A., Clarke H.J., Wong T., Chiang V., Luis E., Estevez A., et al. Molecular basis fornegative regulation of the glucagon receptor. Proc. Natl. Acad. Sci. USA 2012, 109:14393-14398.
22. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
23. Liu Z., Kim W., Chen Z., Shin Y.K., Carlson O.D., Fiori J.L., Xin L., Napora J.K., Short R., Odetunde J.O., et al. Insulin and glucagon regulate pancreatic α-cell proliferation. PLoS ONE 2011, 6:e16096.
24. Longuet C., Robledo A.M., Dean E.D., Dai C., Ali S., McGuinness I., de Chavez V., Vuguin P.M., Charron M.J., Powers A.C., Drucker D.J. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes 2013, 62:1196-1205.
25. Matveyenko A.V., Butler P.C. Relationship between β-cell mass and diabetes onset. Diabetes Obes. Metab. 2008, 10(Suppl 4):23-31.
26. Morris S.M. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 2002, 22:87-105.
27. Mukund S., Shang Y., Clarke H.J., Madjidi A., Corn J.E., Kates L., Kolumam G., Chiang V., Luis E., Murray J., et al. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J.Biol. Chem. 2013, 288:36168-36178.
28. Nicklin P., Bergman P., Zhang B., Triantafellow E., Wang H., Nyfeler B., Yang H., Hild M., Kung C., Wilson C., et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009, 136:521-534.
29. Prentki M., Nolan C.J. Islet β cell failure in type 2 diabetes. J.Clin. Invest. 2006, 116:1802-1812.
30. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., Jaspan J.B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J.Clin. Endocrinol. Metab. 1987, 64:106-110.
31. Sloop K.W., Cao J.X., Siesky A.M., Zhang H.Y., Bodenmiller D.M., Cox A.L., Jacobs S.J., Moyers J.S., Owens R.A., Showalter A.D., et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J.Clin. Invest. 2004, 113:1571-1581.
32. Thorel F., Népote V., Avril I., Kohno K., Desgraz R., Chera S., Herrera P.L. Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss. Nature 2010, 464:1149-1154.
33. Unger R.H., Cherrington A.D. Glucagonocentric restructuring ofdiabetes: a pathophysiologic and therapeutic makeover. J.Clin. Invest. 2012, 122:4-12.
34. Vuguin P.M., Kedees M.H., Cui L., Guz Y., Gelling R.W., Nejathaim M., Charron M.J., Teitelman G. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 2006, 147:3995-4006.
35. Watanabe C., Seino Y., Miyahira H., Yamamoto M., Fukami A., Ozaki N., Takagishi Y., Sato J., Fukuwatari T., Shibata K., et al. Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 2012, 61:74-84.
36. Webb G.C., Akbar M.S., Zhao C., Swift H.H., Steiner D.F. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and α-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 2002, 51:398-405.
37. Yu R. Pancreatic α-cell hyperplasia: facts and myths. J.Clin. Endocrinol. Metab. 2014, 99:748-756.